JOHN A. DAWSON, CBE

Under John’s leadership, Oxford Biomedica’s success resulted in it entering the FTSE 250 index in 2020. John was subsequently awarded a CBE for services to UK life science in recognition of the unprecedented speed and success at which Oxford Biomedica delivered the COVID-19 vaccine.

Prior to Oxford Biomedica, John held various senior executive roles including at Cephalon, Inc. where for most of his tenure he was Managing Director for Europe.

Prior to this, he served as the Financial Director for Serono UK. Mr. Dawson is a Chartered Accountant and holds a BSc in Mathematics from Swansea University.

John is a non-executive director at Ergomed, which provides specialized services to the pharmaceutical industry, Chinese Speciality Pharma Ltd., which brings innovative specialty and rare disease products to China, and Norgine, a leading European specialist pharmaceutical company that has been bringing transformative products to patients for over a century.